Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing BLUE’s new SCD results from ASH 2018 and the sickle cell treatment landscape.

Ticker(s): BLUE, GBT

Who's the expert?

Name: Dr Lewis Hsu - MD/ PhD

Institution: University of Illinois

  • Professor of Pediatric Hematology-Oncology and Director of Pediatric Sickle Cell.
  • Currently manages 170 patients with sickle cell; Active investigator in multicenter clinical trials of potential therapies for sickle cell sponsored by pharmaceutical companies and by NIH
  • Research experience with mouse models and human studies on vascular adhesion of blood cells and inflammation as contributors to sickle vaso-occlusive pain, partial chimeric stem cell transplant for cure, sickle acute chest syndrome, priapism, and nitric oxide therapy

Interview Goal
To speak to an expert to better understand BlueBird Bio's new data presented at ASH 2018 on their LentiGlobin gene therapy product. This call will also look to better understand current treatment paradigms and how patients/ physicians choose and will choose therapies.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.